Table 3.
Overall (N = 180) |
TA-TAVI (N = 90) | TF-TAVI (N = 90) | p | |
---|---|---|---|---|
Sapien™ and Sapien XT™ | 146 (81%) | 86 (96%) | 60 (67%) | |
Sapien 3™ | 8 (4%) | 4 (4%) | 4 (4%) | |
CoreValve™ | 26 (29%) | NA | 26 (29%) | |
Valve-in-valve in degenerated bioprosthesis | 12 (7%) | 7 (8%) | 5 (6%) | 0.550a |
Bailout valve-in-valve for migration or malpositioning | 7 (4%) | 3 (3%) | 4 (4%) | 1 |
Mean valve size (mm) | 25 ± 2.1 | 25 ± 1.9 | 25 ± 2.2 | |
Valve size distribution | ||||
23 mm | 75 (42%) | 40 (44%) | 35 (39%) | |
26 mm | 77 (43%) | 43 (48%) | 44 (49%) | |
29 mm | 14 (8%) | 7 (8%) | 7 (8%) | |
31 mm | 4 (4%) | 0 (0%) | 4 (4%) | |
Procedural time (min) | 113 ± 48 | 98 ± 33 | 127 ± 56 | <0.001 |
Data presented as mean ± SD or N (%)
a Chi2 value, otherwise it’s a Fischer test or a T-Test value